BMY

Bristol-Myers Squibb
D

BMY

Arincen68/100B

If you had invested in Bristol-Myers Squibb ago, it would be worth $1,467 today, against $3,836 in SPY and $5,891 in QQQ.

ArincenArincen ScoreBeta

68/100

Six parts of the company, five checks each, from its own reported figures. A part scores the checks it passes out of 10; the score is their average out of 100.

Profitability6

Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.

Cash10

Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.

Valuation10

Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.

Growth2.5

Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.

Financial strength4

Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.

Shareholders8

Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.

Figures to FY2025; the price as of today.

Bristol-Myers Squibb key facts

Style
Value stock · 9.3/10Growth 1.0 · Value 9.3 · Dividend 9.3
Day range
58.740 – 59.800
52-week range
45.270 – 68.640
Market capitalization
120.89B USD
P/E
13.08
PEG ratio
1.76
EPS
4.52
Div Yield
4.26%
EPS growth forecast (FY2026)
+4.9%
Volume
353,042
Beta
0.23
ESG score
69.8/100Environment 74 · Social 63 · Governance 72
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Christopher Boerner
Employees
33K
Website
bms.com
IPO date
1 Jun 1972

Bristol-Myers Squibb earnings

Next earnings · Q4 FY2026
EPS estimate
1.53 USD
Revenue estimate
12.66B USD
Last quarter · Q3 FY2026
EPS1.35Beat +22.7%Revenue13.07BBeat +2.7%

Revenue

ReportedEstimate

EPS

ReportedEstimate
PeriodReport dateEPS estimateReported EPSSurpriseEPS growthRevenue estimateReported revenueSurpriseRevenue growth
Q1 FY20281.37——-10.21%10.62B——-6.23%
Q4 FY20271.60——+4.29%12.41B——-1.98%
Q1 FY20271.52——-3.73%11.33B——-1.39%
Q4 FY20261.53——+21.43%12.66B——+1.29%
Q3 FY20261.101.35+22.73%-17.18%12.72B13.07B+2.72%+6.93%
Q2 FY20261.602.04+27.50%+39.73%11.74B12.97B+10.51%+5.74%
Q1 FY20261.421.58+11.27%-12.22%10.93B11.49B+5.14%+2.57%
Q4 FY20251.231.26+2.44%-24.55%12.28B12.50B+1.80%+1.30%
Q3 FY20251.521.63+7.24%-9.44%11.85B12.22B+3.14%+2.77%
Q2 FY20251.091.46+33.94%-29.47%11.44B12.27B+7.21%+0.56%

Analysts' estimates for FY2026 over the last 7 days:EPS Revenue How the estimates moved

Bristol-Myers Squibb analyst forecast

12-month price target
66.14 USD
+11.84%

Analysts' 1-year price targets range from 41.00 to 78.00, with an average of 66.14.

Past year
1-year forecast
Strong sellStrong buy
Hold
16 ratings
Buy
7
Hold
8
Sell
1

12-month price target

Highest target78.00
Average target66.14
Lowest target41.00
Current price59.14

Bristol-Myers Squibb valuation

Price to earnings ratio (TTM)
13.08
Forward P/E (FY2026)
9.16
Price to sales (TTM)
2.42
Price to book
5.17
EV / EBITDA (TTM)
10.11

Capital structure

Market capitalization
120.89B USD
+
Total debt
44.81B USD
−
Cash and short-term investments
12.58B USD
=
Enterprise value
153.12B USD

Valuation over time

P/EForward P/EForward P/E · EstimateEstimate
Fiscal yearP/EForward P/EP/SP/BEV/EBITDA
FY2028 (est.)11.17————
FY2027 (est.)8.8311.17———
FY2026 (est.)9.168.83———
Now (TTM)13.088.872.425.1710.11
FY202515.598.362.285.969.65
FY2024-12.839.262.377.0249.08
FY202313.229.742.363.617.03
FY202224.239.743.324.939.62
FY202119.798.442.993.858.45

Bristol-Myers Squibb against its own history

Each figure in the latest fiscal year against the same figure from FY2021 to FY2025: the range, its median (the line) and the latest (the dot, green on the good side of the median). The P/E is today's against its daily readings of five years.

Its peers: Pfizer, Gilead Sciences, Amgen, Merck & Co., Biogen, and AbbVie, the US Drug Manufacturers - General companies closest to it in size, each in its own latest fiscal year: their median (the line) and its rank among them, first being the best.

  • Gross marginBelow its median71.1%
    71.1%78.6%
    Against its peers: 5 of 7Peers' median 73.2%
  • Operating marginHighest in 5 years28.5%
    12.2%28.5%
    Against its peers: 3 of 7Peers' median 26.4%
  • Net marginAt its median14.6%
    -18.5%17.8%
    Against its peers: 4 of 7Peers' median 17.0%
  • Return on equityHighest in 5 years38.2%
    -54.8%38.2%
    Against its peers: 2 of 6Peers' median 34.7%
  • Free cash flow marginBelow its median26.7%
    25.9%32.8%
    Against its peers: 3 of 7Peers' median 21.4%
  • Revenue growthAt its median-0.2%
    -2.5%9.1%
    Against its peers: 6 of 7Peers' median 2.3%
  • Debt to EBITDAAbove its median3.10×
    2.12×16.16×
    Against its peers: 4 of 7Peers' median 2.95×
  • Current ratioAt its median1.26
    1.251.52
    Against its peers: 4 of 7Peers' median 1.35

Peers: US companies of the same industry (of its sector when the industry has too few) from a tenth to ten times its market value, the six closest in size. Updated weekly.

Bristol-Myers Squibb growth and profitability

Revenue (TTM)
50.03B USD
Net income (TTM)
9.24B USD
Gross margin
69.24%
Operating margin
26.07%
Net margin
18.47%

Revenue / Net income

Revenue Net income Net margin
PeriodRevenueGrowthNet incomeGrowthGross marginOperating marginNet marginEBITDAGrowth
FY202548.20B-0.22%7.05B—71.08%28.48%14.64%15.23B+380.74%
FY202448.30B+7.32%-8.95B-211.50%71.08%12.19%-18.53%3.17B-83.64%
FY202345.01B-2.50%8.03B+26.84%76.24%18.21%17.83%19.37B+0.75%
FY202246.16B-0.49%6.33B-9.54%78.04%19.72%13.71%19.22B-4.46%
FY202146.39B+9.09%6.99B—78.57%18.40%15.08%20.12B+308.16%

Bristol-Myers Squibb revenue breakdown

By product

FY2025
Eliquis: 30.0%Opdivo: 20.9%Orencia: 7.7%Revlimid: 6.1%Yervoy: 6.0%Pomalyst/Imnovid: 5.7%Reblozyl: 4.8%Other Growth Brands: 4.0%Breyanzi: 2.8%Opdualag: 2.5%Camzyos: 2.2%Other Legacy Brands: 1.7%Zeposia: 1.2%Sprycel: 1.0%Abecma: 0.9%Abraxane: 0.8%Sotyktu: 0.6%Opdivo Ovantig: 0.5%Krazati: 0.4%Cobenfy: 0.3%30.0%Eliquis20.9%Opdivo7.7%Orencia6.1%Revlimid6.0%Yervoy5.7%Pomalyst/Imnovid4.8%Reblozyl4.0%Other Growth Brands2.8%Breyanzi2.5%Opdualag2.2%Camzyos1.7%Other Legacy Brands1.2%Zeposia1.0%Sprycel
SegmentRevenueShare of revenueChange on the year
Eliquis14.44B30.0%+8.3%
Opdivo10.05B20.9%+8.0%
Orencia3.71B7.7%+0.6%
Revlimid2.95B6.1%-48.9%
Yervoy2.90B6.0%+14.6%
Pomalyst/Imnovid2.73B5.7%-22.9%
Reblozyl2.33B4.8%+31.2%
Other Growth Brands1.92B4.0%+19.9%
Breyanzi1.36B2.8%+81.8%
Opdualag1.19B2.5%+27.7%
Camzyos1.07B2.2%+77.4%
Other Legacy Brands798.00M1.7%-13.7%
Zeposia577.00M1.2%+1.9%
Sprycel493.00M1.0%-61.7%
Abecma427.00M0.9%+5.2%
Abraxane368.00M0.8%-57.9%
Sotyktu291.00M0.6%+18.3%
Opdivo Ovantig238.00M0.5%—
Krazati205.00M0.4%+62.7%
Cobenfy155.00M0.3%+1,450.0%

By region

FY2025
United States: 69.1%Other: 28.7%Other Region: 2.3%69.1%United States28.7%Other2.3%Other Region
RegionRevenueShare of revenueChange on the year
United States33.28B69.1%-2.4%
Other13.83B28.7%—
Other Region1.09B2.3%+9.1%

How Bristol-Myers Squibb makes its money

Eliquis14.44B 30.0%
Opdivo10.05B 20.9%
Orencia3.71B 7.7%
Revlimid2.95B 6.1%
Yervoy2.90B 6.0%
Pomalyst/Imnovid2.73B 5.7%
Reblozyl2.33B 4.8%
Other Growth Brands1.92B 4.0%
Breyanzi1.36B 2.8%
Opdualag1.19B 2.5%
Camzyos1.07B 2.2%
Other Legacy Brands798.00M 1.7%
Zeposia577.00M 1.2%
Sprycel493.00M 1.0%
Abecma427.00M 0.9%
Abraxane368.00M 0.8%
Sotyktu291.00M 0.6%
Opdivo Ovantig238.00M 0.5%
Krazati205.00M 0.4%
Cobenfy155.00M 0.3%
Revenue48.20B 100.0%
Cost of revenue13.94B 28.9%
Gross profit34.26B 71.1%
Research and development9.95B 20.6%
Selling and administration7.27B 15.1%
Other operating expenses3.32B 6.9%
Operating income13.72B 28.5%
Tax2.27B 4.7%
Other expense4.40B 9.1%
Net income7.05B 14.6%

FY2025, in USD. Each band is as wide as its money; the percentage is its share of revenue.

Bristol-Myers Squibb dividends

Annual dividend
2.52 USD
Dividend yield (indicated)
4.26%
Payout ratio
55.75%
Years of dividend growth
19
Frequency
Quarterly
Last payment
0.63 USD
Last ex-dividend date
2 Oct 2026
Last payment date
2 Nov 2026

Dividends per share

Year2025202420232022202120202019201820172016
Dividends per share2.482.402.282.161.961.801.641.601.561.52

Bristol-Myers Squibb financial health

Cash and short-term investments
12.58B USD
Total debt
44.81B USD
Net cash
-32.23B USD
Free cash flow (TTM)
9.29B USD
Current ratio
1.59
Debt to equity
1.91
Piotroski score
7 / 9
Altman Z-score
2.68

Cash, debt and free cash flow

Cash and short-term investments Total debt Free cash flow
Fiscal yearCash and short-term investmentsTotal debtFree cash flow
FY202510.67B47.14B12.85B
FY202410.86B51.20B13.94B
FY202312.28B41.46B12.65B
FY20229.25B40.72B11.95B
FY202117.22B45.60B15.23B

Bristol-Myers Squibb ownership

Institutions
80.22%
Institutional holders
2,664 (+28)
Free float
99.68%

Who owns the shares

Institutions 80.2% Others 19.8%
As of 30 Sept 2026

Shares free to trade

Free float 2.04B shares ·99.7% Closely held 6.47M shares ·0.3%

Closely held shares belong to insiders, founders and owners of more than 5%, and seldom change hands. The free float is the rest: the shares anyone can buy and sell.

Insider trading

QuarterPurchasesSalesShares acquiredShares disposed of
Q4 20260128.01K45.19K
Q3 20260256.59K87.57K
Q2 20260236.56K69.55K
Q1 2026001.17M404.23K

Shares outstanding

Basic shares Diluted shares Change in diluted shares
Fiscal yearBasic sharesDiluted sharesChange in diluted shares
FY20252.04B2.04B+0.69%
FY20242.03B2.03B-2.45%
FY20232.07B2.08B-3.17%
FY20222.13B2.15B-4.41%
FY20212.22B2.25B-0.58%

Source: Financial Modeling PrepVerified against SEC filings

Related Instruments News

Title: Bristol/Myers Squibb Co

Sector: Healthcare
Industry: Drug Manufacturers - General
The Bristol Myers Squibb Company (BMS) is an American pharmaceutical firm. Headquartered in New York City, the company has multinational interests supporting its operations that manufacture, distribute and market biopharmaceutical products. The company’s products are used in human therapeutic applications that include cancer, HIV/AIDS, cardiovascular disease, diabetes, hepatitis, rheumatoid arthritis and psychiatric disorders. The Bristol Myers Squibb Company is one of the world's largest pharmaceutical companies and is a consistent member of the Fortune 500 list of the largest US corporations by revenue.

Common questions about Bristol-Myers Squibb stock